NEW YORK, June 30, 2016 /PRNewswire/ --
On Wednesday, June 29, 2016, the
NASDAQ Composite ended the trading session at 4,779.25, up 1.86%;
the Dow Jones Industrial Average advanced 1.64%, to finish at
17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The
gains were broad based as all the sectors ended the session in
positive. Stock-Callers.com has initiated coverage on the following
equities: Agenus Inc. (NASDAQ: AGEN), BioCryst Pharmaceuticals Inc.
(NASDAQ: BCRX), Cempra Inc. (NASDAQ: CEMP), and Hemispherx
Biopharma Inc. (NYSEMKT: HEB). Learn more about these stocks by
accessing their free trade alerts at:
http://stock-callers.com/registration
Agenus Inc., an immuno-oncology Company, focuses on the
discovery and development of treatments that engage the body's
immune system for patients suffering with cancer. The stock
finished Wednesday's session 2.32% higher at $3.97 with a total volume of 729,417 shares
traded. The stock is trading above its 50-day moving average by
2.59%. Agenus's stock has a Relative Strength Index (RSI) of 49.49.
The Company was founded in 1994 and is headquartered in
Lexington, Massachusetts. Sign up
and read the free notes on AGEN at:
http://stock-callers.com/registration/?symbol=AGEN
BioCryst Pharmaceuticals Inc., a biotechnology Company, designs,
optimizes, and develops small molecule drugs that block key enzymes
involved in the pathogenesis of diseases. The stock advanced 3.56%
to close the day at $2.91 with a
total volume of 481,707 shares traded. The stock is trading 8.11%
below its 50-day moving average. Additionally, BioCryst
Pharmaceuticals' stock has an RSI of 44.11. The Company was founded
in 1986 and is headquartered in Durham,
North Carolina. The complimentary notes on BCRX can be
downloaded in PDF format at:
http://stock-callers.com/registration/?symbol=BCRX
On Wednesday, shares in Cempra Inc. ended the session 1.60% higher
at $16.54 with a total volume of
615,657 shares traded. The clinical-stage pharmaceutical Company
focuses on developing antibiotics to meet medical needs in the
treatment of bacterial infectious diseases in North America. The stock is trading 5.39%
below its 50-day moving average. Moreover, shares of Cempra have an
RSI of 38.00. The Company was founded in 2005 and is headquartered
in Chapel Hill, North Carolina.
Register for free on Stock-Callers.com and access the latest
research on CEMP at:
http://stock-callers.com/registration/?symbol=CEMP
On Wednesday, shares in Hemispherx Biopharma Inc. ended the day
2.38% higher at $0.12 with a total
volume of 555,117 shares traded. The specialty pharmaceutical
Company, engages in the clinical development of new drug therapies
based on natural immune system enhancing technologies for the
treatment of viral and immune based chronic disorders in
the United States. The stock is
trading below its 50-day moving average by 5.67%. Furthermore,
shares of Hemispherx Biopharma have an RSI of 45.11. The Company
was founded in 1990 and is headquartered in Philadelphia, Pennsylvania. Get free access to
your trade alert on HEB at:
http://stock-callers.com/registration/?symbol=HEB
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com . Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA